Alephoson Biopharmaceuticals Limited is proud to announce that it has been awarded third place in the SAPA (Sino-American Pharmaceutical Professionals Association) Roadshow held on June 25-26, 2021. This recognition is a testament to the company’s commitment to innovation and its mission to improve global healthcare through biopharmaceutical research and development.
The SAPA Roadshow is an annual event that brings together professionals in the pharmaceutical and biotech industry, investors, and entrepreneurs to showcase the latest scientific breakthroughs, innovative technologies, and emerging companies in the field of life sciences. This year’s event was held virtually due to the ongoing COVID-19 pandemic.
Alephoson Biopharmaceuticals Limited’s presentation at the SAPA Roadshow highlighted the company’s innovative method – CePPA (Cell Penetration Protein Alternation) to treat eye diseases including macular degeneration and uveitis by using eye drops. This delivery method can greatly improve patient compliance and treatment effects. In contrast, the traditional therapy implements intraocular injections periodically and results in strong side effects as well as low patient compliance. Alephoson’s eye drop therapy has the potential to revolutionize the treatment of common eye diseases.
Alephoson Biopharmaceuticals Founder and CEO Dr. Benjamin Lee Shares Insights at APAO and ARVO Conferences
Dr. Lee and Dr. Yong at APAO
2023 APAO (Asia-Pacific Academy of Ophthalmology) Congress in Kuala Lumpur, Malaysia
奥朗参加亚洲医疗健康高峰论坛
奧朗生物醫藥有限公司在中美藥學專業人士協會SAPA路演中獲得第三名
奧朗生物醫藥有限公司很榮幸宣布，在於2021年6月25日至26日舉辦的SAPA（中美藥學專業人士協會）路演中獲得第三名。這個獎項證明了公司對創新的承諾，以及通過生物製藥研究和開發來改善全球醫療保健的使命。
SAPA路演是一年一度的活動，聚集了製藥和生物技術行業的專業人士、投資者和企業家，展示了生命科學領域最新的科學突破、創新技術和新興企業。今年的活動由於持續的COVID-19大流行而以虛擬形式舉行。
楊博士在 SAPA 路演上的演講重點介紹了本公司的創新方法 – CePPA（細胞穿模肽技術），通過使用滴眼液治療包括黃斑病變和葡萄膜炎等眼部疾病。這種給藥方式可以大大提高患者的依從性和治療效果。相比之下，傳統療法採用周期性眼內注射，副作用大，患者依從性低。本公司的滴眼液療法有可能革命性地改變常見眼病的治療方法。
奥朗生物医药有限公司在中美药学专业人士协会SAPA路演中获得第三名
奥朗生物医药有限公司很荣幸宣布，在于2021年6月25日至26日举办的SAPA（中美药学专业人士协会）路演中获得第三名。这个奖项证明了公司对创新的承诺，以及通过生物制药研究和开发来改善全球医疗保健的使命。
SAPA路演是一年一度的活动，聚集了制药和生物技术行业的专业人士、投资者和企业家，展示了生命科学领域最新的科学突破、创新技术和新兴企业。今年的活动由于持续的COVID-19大流行而以虚拟形式举行。
楊博士在 SAPA 路演上的演讲重点介绍了本公司的创新方法 – CePPA（细胞穿模肽技术），通过使用滴眼液治疗包括黄斑变性和葡萄膜炎在内的眼部疾病。 这种给药方式可以大大提高患者的依从性和治疗效果。 相比之下，传统疗法采用周期性眼内注射，副作用大，患者依从性低。 本公司的滴眼液疗法有可能革命性地改变常见眼病的治疗方法。
奧朗-香港科學園 公關活動日
Alephoson collaboration with Hong Kong Science Park
Alephoson collaborated with the Hong Kong Science Park (HKSTP) team hosted a knowledge sharing session which included a general presentation by HKSTP, followed by a presentation by Alephoson and then a tour around the biotechnology shared facilities. Attendees included students who were interested in a career in the biotech area, Pearl River Delta Angels (PRD Angels members), representatives of family offices and the French Trade Commission, amongst others.
Alephoson Biopharmaceuticals Limited Takes Third Place in SAPA Roadshow
Alephoson Biopharmaceuticals Limited is proud to announce that it has been awarded third place in the SAPA (Sino-American Pharmaceutical Professionals Association) Roadshow held on June 25-26, 2021. This recognition is a testament to the company’s commitment to innovation and its mission to improve global healthcare through biopharmaceutical research and development.
The SAPA Roadshow is an annual event that brings together professionals in the pharmaceutical and biotech industry, investors, and entrepreneurs to showcase the latest scientific breakthroughs, innovative technologies, and emerging companies in the field of life sciences. This year’s event was held virtually due to the ongoing COVID-19 pandemic.
Alephoson Biopharmaceuticals Limited’s presentation at the SAPA Roadshow highlighted the company’s innovative method – CePPA (Cell Penetration Protein Alternation) to treat eye diseases including macular degeneration and uveitis by using eye drops. This delivery method can greatly improve patient compliance and treatment effects. In contrast, the traditional therapy implements intraocular injections periodically and results in strong side effects as well as low patient compliance. Alephoson’s eye drop therapy has the potential to revolutionize the treatment of common eye diseases.